New seed monopolies through NGT
previous pauseresume next

Meat from cloned animals – on the menu in Europe?

Testbiotech report warns market getting out of control
Tuesday, 4 May 2010
Munich / Brussels

Material from cloned animals and their offspring is likely to be on the European market already. There is currently no legal regulation which would effectively exclude these imports. No public register is available to provide transparency if cloned animals, their offspring or breeding material is imported into the EU.

Seed purity as important aspect of risk management

A report on seed purity and risk related aspects was yesterday/ today published by IFOAM (International Federation of Organic Agriculture Movements). The authors are Christoph Then at Testbiotech and Matthias Stolze at the FiBL (Research Institute of Organic Agriculture, Switzerland). The study, Economic impacts of labelling thresholds for the adventitious presence of genetically engineered organisms in conventional and organic seed, shows that seed purity is vitally important in ensuring transparency, segregation and freedom of choice for consumers.

Approval of Bt maize 1507 should be withheld

EFSA acting irresponsibly says Testbiotech
Thursday, 22 April 2010

A recent Testbiotech report showed that the risks associated with Bt maize 1507, which is about to be authorised for cultivation in the EU, were incorrectly assessed by the EFSA (European Food Safety Authority). Despite the fact that this type of maize has an an extremely high concentration of insecticide in its pollen the EFSA did not request any investigations be carried out on butterflies or other prevalent insects in Europe.

Testbiotech challenges patent on human egg cells

Merck Serono company even filed patents on transplantation of human organs and embryos
Wednesday, 14 April 2010

German based NGO Testbiotech has filed an opposition against a patent held by the Merck Serono company at the European Patent Office in Munich, Germany. Patent EP 1794287 covers a process for the production and use of human oocytes (egg cells). This claim is considered as being in conflict with European Patent law, which excludes patents on the human body at the various stages of its development.


Alle | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009